fbpx

Day

December 7, 2015
Envarsus® XR is Indicated for Patients Converted from Tacrolimus Immediate-release FormulationsVeloxis Pharmaceuticals A/S (OMX: VELO) today announced the U.S. launch of Envarsus® XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from immediate release tacrolimus products to once-daily Envarsus® XR. 

Nyheder

New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020
A female dog may well be the answer
24. January 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge